Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
i hope....but i think that is not easy
gooo AVXL...
The post-Biogen , POst-Amuloid Wolrd for Alzheimer´s disease
https://seekingalpha.com/article/4435705-post-biogen-post-amyloid-world-for-alzheimers-disease
Putin, 68, is suffering from Parkinson's disease
one good costumer for Anavex
https://www.dailymail.co.uk/news/article-8919975/Putin-quit-January-amid-fears-Parkinsons-disease-Moscow-sources-claim.html
avxl-stock-ready-to-make-a-big-move
https://insiderfinancial.com/avxl-stock-ready-to-make-a-big-move/180478/
Conferencia Dr. Kate vedio
the unique pattern is that there arent any news
Old news..
A novel synthetic DNA vaccine elicits protective immune responses against Powassan virus
https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0008788
https://pubmed.ncbi.nlm.nih.gov/33119599/
Why Inovio Could Double In Price In Just Days
Thirdly Invovio (Nasdaq:INO)
Back in July, INO stock was super hot, it traded above $33 a share. Inovio had tested INO-4800 on non-human primates, and the results were highly promising.
The research study found that “The reduced viral loads following exposure to SARS-CoV-2 infection at this timeframe demonstrate an important durable impact mediated by INO-4800.”
This was not only encouraging, but perhaps historic. As Inovio reported, this trial marked “the first time a vaccine protection in non-human primates was reported from memory immune responses as previously reported monkey vaccine challenge studies were conducted at the time near their peak immune responses…”
On top of that, in August, Inovio reported that all participants in a 38-person trial demonstrated overall immune responses. Plus, there were no reported serious adverse events. Overall, both the company and its investors were in celebration mode.
Inovio stock sold off after the U.S. Food and Drug Administration notified Inovio that it “has additional questions about the company’s planned Phase 2/3 trial of its COVID-19 vaccine candidate INO-4800,” as reported by Inovio.
Market participants reacted harshly, slamming the INO share price. Risk-tolerant traders should consider the possibility that this was an overreaction.
Just because the Phase 2/3 trial has been put on pause, doesn’t mean that it is tabled permanently. The FDA is giving Inovio a chance to respond to its questions. And if all goes well, the trial could still be in progress in November.
Much of this piece on Inovio is credited to talented writer Louis Navellier from InvestorPlace Research.
Once FDA clears Inovio this stock could double over night. I believe buying now in the $10 range is a bet worth taking.
https://seekingalpha.com/instablog/51307855-tradeinvestments2019/5514870-why-workhorse-virgin-galactic-inovio-double-in-price-in-just-days
Vacuna INO-4800 Covid-19
https://vaxbase.org/ino-4800-covid-19-vaccine/
Totally Agree
interview with a woman volunteering in the #Inovio trial
ICYMI: Yesterday, I had the opportunity to catch up with #StellaSexton the local woman volunteering in the #Inovio trial, it’s the first DNA vaccine using electric pulses to inject the drug into the skin.
— Talia Kirkland (@talia_kirkland) October 29, 2020
When I asked Sexton was the decision easy she had this to say: #CBS21NEWS pic.twitter.com/zrH52DUUAM
Acadia Pharmaceuticals to Present New Scientific Data on Pimavanserin in Neurodegenerative Diseases at the 13th Clinical Trials on Alzheimer's Disease (CTAD) Conference
https://marketwirenews.com/news-releases/acadia-pharmaceuticals-to-present-new-scientific-dat-5775743174984122.html?i=ib
A European Observational Study to
Evaluate the Safety and the Effectiveness of
Safinamide in Routine Clinical Practice:
The SYNAPSES Trial
https://content.iospress.com/download/journal-of-parkinsons-disease/jpd202224?id=journal-of-parkinsons-disease%2Fjpd202224
30% up---
New trial provides hope for incurable disease
https://www.alfredhealth.org.au/news/new-trial-provides-hope-for-incurable-disease/
Parkinson’s Disease and Appendectomy are Related—Study
http://industrynewstimes.com/311/parkinsons-disease-and-appendectomy-are-related-study/
Anavex 2-73 price by mg.
Tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride
https://aobious.com/aobious/sigma-receptors/12980-anavex-2-73.html
People with Parkinson's disease dementia sought for drug trial
https://www.thesenior.com.au/story/6129556/trial-of-new-drug-to-treat-parkinsons-dementia/
go, go, go, 3,50
ANAVEX2-73 for Treatment of Early Alzheimer's Disease
Data from clinicaltrials.gov - Curated by EPG Health - Last updated 15 May 2019 Share +
https://www.epgonline.org/uk/trials/anavex2-73-for-treatment-of-early-alzheimer-s-disease.html
to the moonnnnn 5% UP
Q2 2019 Anavex Life Sciences Corp Earnings Call transcript
https://finance.yahoo.com/news/edited-transcript-avxl-earnings-conference-005707425.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAABSKvJwEd8rW0akLXlJiMInEQein8XJL_1bvZiZGMZ_vTS1mb8naHX16xma2ozP_SD9dP6tV8xqR9kxtabZV_SKfZCSiaCeA4hZMHZ7Ev4-5rgbsdDzG1jOWeaKACeaddKU8jhQn94bToFe8E54wGELseVPrnHw9C8a5SIg1iyqS
Zacks: Los analistas anticipan que Anavex Life Sciences Corp (AVXL) anunciará – $ 0.12 Ganancias por acción
https://periodicoprincipal.com/2019/05/08/zacks-los-analistas-anticipan-que-anavex-life-sciences-corp-avxl-anunciara-0-12-ganancias-por-accion/
Wedbush Securities Inc. Takes $43,000 Position in Anavex Life
https://www.fidaily.com/2019/05/06/wedbush-securities-inc-purchases-new-position-in-anavex-life-sciences-corp-avxl.html
Submission of Matters to a Vote of Security Holders
https://www.sec.gov/Archives/edgar/data/1314052/000161577419005452/s117292_8k.htm
And viceversa
Visceral Pain Therapeutics- Pipeline Analysis 2018, Clinical Trials & Results
https://fashionjournal24.com/visceral-pain-therapeutics-pipeline-analysis-2018-clinical-trials-results/
Will Biogen Inc (NASDAQ: BIIB) Buy Anavex Life Sciences Corp (NASDAQ: AVXL)?
https://insiderfinancial.com/biogen-inc-nasdaq-biib-anavex-life-sciences-corp-nasdaq-avxl
anavex The unic parkinson study currenly in europe doing in Spain
http://www.cronicanorte.es/el-numero-de-pacientes-con-parkinson-se-duplicara-en-los-proximos-20-anos/134489
“Muscarinic M1 Agonist” | Pipeline Insight Research Report, 2019
https://rochesterleader.com/muscarinic-m1-agonist-pipeline-insight-research-report-2019/
Key-players analyzed in Muscarinic M1 Agonist Pipeline Insight Report: Heptares Therapeutics, WinSanTor, Anavex Life Sciences, Mithridion, Boehringer Ingelheim, Glenmark Pharmaceuticals Ltd, & list continues,
anavex target=300$
if anavex have a price of 140.000.000$ the stock =2,96 = +/-= 50.000.000 Stocks
today BIOGEN lost 15.000.000.000$ If this capital can be moved to AVXL
15.000.000.000$ / 50M stocks, = price of AVXL=300$ by stock.
congratulations guys...
Spanish Radio interview about the Anavex F2study/parkinson
the first 12 minutes
(apologies but is in spanish)
https://www.sendasenior.com/Programa-n%C2%BA-59_a6214.html
BIENVENIDA ELSASARA
Yo tambien soy de España, Barcelona
Wellcome Elsara
Im too from Spain (Barcelona)
Anavex Life Sciences advancing its Parkinson's disease therapy through the pipeline